Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Digital Transformation in the Pharmaceuticals Industry-Companies-to-Action, 2018 - Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities | ||
By: PR Newswire Association LLC. - 21 Sep 2018 | Back to overview list |
|
DUBLIN, Sept 21, 2018 /PRNewswire/ -- The "Digital Transformation in the Pharmaceuticals Industry-Companies-to-Action, 2018" report has been added to ResearchAndMarkets.com's offering. The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers-digitally enabled by the entry of non-traditional tech companies such as Apple, Facebook, and Google-pushing pharmaceutical companies to go beyond-the-pill. However, in the midst of this chaos, there are pioneering companies offering solutions that apply cutting-edge digital technologies such as AI, Big Data and analytics, cloud, mobile, blockchain, and Internet of Things (IoT) to build digital convergence across the pharmaceutical value chain, covering R&D, manufacturing and operations, marketing, and patient connect. This Companies to Action (C2A) analysis puts the spotlight on such game-changing, tech-enabled participants and how they are altering the status-quo by highlighting novel monetization models and strategic investment opportunities. Research Scope The key objective of this study is to highlight current market dynamics, key market participants, customer segments, and evolving business opportunities. The study aims to identify pioneering companies that are capable of shaping the future through best practices implementation, visionary leadership, and innovation in business models. The company profiles offer insights around key solution offerings, target customer segments, service differentiators, and future growth strategies. Further, the global study provides an analysis of companies segregated by market segments such as: smart R&D, flexible manufacturing, connected patients, and digital pharmacy. The analysis covers technologies such as Artificial intelligence (AI), Big Data and analytics, crowdsourcing, mobile, Industrial IoT (IIoT), IoT, cloud, blockchain, eCommerce, and so on. The participants mentioned in the study are iSolve, Zephyr Health, PillPack, Proteus Digital Health, BenevolentAI, Elemental Machines, Exscientia, Science 37, Transparency Life Sciences, and uMotif. It also lists the wider universe of companies that were assessed for this analysis. These companies were chosen based factors such as innovative technology development and application, hitting the right focus areas, proven success and industry recognition, and enhanced client collaborations.
Key Topics Covered: 1. Executive Summary
2. Companies-to-Action Overview
3. Market Overview
4. Companies-to-Action Profiles
5. The Last Word
6. Appendix
For more information about this report visit https://www.researchandmarkets.com/research/82blcx/digital?w=5 Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager. Media Contact: Research and Markets
View original content to download multimedia:http://www.prnewswire.com/news-releases/digital-transformation-in-the-pharmaceuticals-industry-companies-to-action-2018---value-based-care-patient-data-digitization-and-collaborative-technology-deployment-offer-investment-opportunities-300716853.html SOURCE Research and Markets |
||
|
||
Copyright 2018 PR Newswire Association LLC. | Back to overview list |